Celldex plans Life After Glembatumumab, Cutting 2 More Drugs From Pipeline
Still reeling from the failure of its lead breast cancer candidate glembatumumab vedotin last month, Celldex has culled another two pipeline projects and now says it will focus its R&D efforts mainlyRead More…